Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
1
17%
Ph not_applicable
1
17%
Ph phase_2
2
33%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

unknown2
Completed2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (33.3%)
Phase 32 (33.3%)
Phase 41 (16.7%)
N/A1 (16.7%)

Trials by Status

unknown233%
completed233%
not_yet_recruiting233%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

NCT06643442
not_yet_recruitingphase_2

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

NCT06012266
unknownphase_3

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

NCT04221152
unknownphase_3

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

NCT04018365
completedphase_4

Short Term Effect of Empagliflozin in Hypertension

NCT04203914
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06643442Phase 2

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

Not Yet Recruiting
NCT06012266Phase 2

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Not Yet Recruiting
NCT04221152Phase 3

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )

Unknown
NCT04018365Phase 3

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance

Unknown
NCT04203914Phase 4

Short Term Effect of Empagliflozin in Hypertension

Completed
NCT03771781Not Applicable

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6